Bristol Myers Squibb stock heads into the open after a 1.9% slide

At the close on September 5, 2026, Bristol Myers Squibb stock ended at USD 66.78 on the NYSE, down 1.9%. The move left the shares near recent lows while the broader S&P 500 saw modest pressure in the same session.

At the close on September 5, 2026, Bristol Myers Squibb stock finished at USD 66.78 on the NYSE, declining 1.9% from the previous session. Market data indicate that this left the shares trading close to a recent indicative level of USD 66.85 seen on September 7, 2026, underscoring continued weakness into today.

September 5, 2026 in numbers

Bristol Myers Squibb Co. (ISIN US0897961004, NYSE: BMY) recorded a prior-session close of USD 66.78 on the NYSE on September 5, 2026, after slipping 1.9% compared with its previous day’s finish, according to ad-hoc market coverage citing MarketBeat data. The decline unfolded against a backdrop of broader market caution around the start of a shortened US trading week, as US equity futures and major indices showed pressure around early September according to a live update from CNBC market coverage. While detailed intraday ranges and volume for Bristol Myers Squibb on September 5, 2026 were not broken out in the cited summary, the confirmed close at USD 66.78 positions the stock slightly below an indicative level of USD 66.85 reported for September 7, 2026, implying only a narrow difference of USD 0.07 between the last completed session and the later indicative quote. This suggests that the 1.9% drop on September 5, 2026 largely defined the stock’s recent trajectory, with subsequent indicative trading levels holding close to that prior close.

Context from institutional positioning also shows ongoing interest in the shares. Filings summarized by MarketBeat and related coverage note sizeable positions built by institutional investors in Bristol Myers Squibb in recent months, tied in part to the firm’s earnings report released on July 30, 2026. In that release, Bristol Myers Squibb reported earnings per share of USD 2.04 for the quarter, beating a consensus of USD 1.60, and revenue of USD 12.97 billion versus expectations of USD 11.74 billion, figures that underpin the valuation backdrop for the stock as it heads into today’s session. The combination of a recent price decline and solid reported fundamentals provides the framework for how investors may weigh the stock after its 1.9% slide in the last completed trading day.

Today’s drivers and upcoming dates

Today, September 8, 2026, Bristol Myers Squibb does not have a confirmed earnings release or major company specific event scheduled within the next few days in the available calendars, with the next notable update referenced in external analysis as falling later in the year according to commentary summarized by Finimize research. That leaves broader market factors and sector sentiment as potential influences on trading, including movements in key US indices such as the S&P 500 and trends in healthcare and biopharmaceutical stocks following recent macroeconomic headlines highlighted by CNBC market coverage. As investors approach the open today, the stock’s latest confirmed close at USD 66.78 on September 5, 2026 and its narrow gap to the indicative USD 66.85 quote seen on September 7, 2026 frame expectations around whether Bristol Myers Squibb can stabilize or continue to trade near the lower end of its recent range, without any major company specific catalyst immediately on the calendar.